Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04DKH
|
|||
Former ID |
DNC004943
|
|||
Drug Name |
NAFTOPIDIL
|
|||
Synonyms |
naftopidil; 57149-07-2; Flivas; KT-611; Naftopidil [INN]; Avishot; Naftopidilum [Latin]; Naftopidil (Flivas); BM-15275; Naftopidil (unspecified); BRN 0629965; CHEMBL142635; C24H28N2O3; 1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy)propan-2-ol; NCGC00015718-06; (+-)-1-(4-(2-Methoxyphenyl)piperazinyl)-3-(1-naphthyloxy)propan-2-ol; 4-(2-Methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl)-1-pioerazineethanol; (RS)-1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(1-naphthyloxy)-2-propanol; DSSTox_RID_80725; DSSTox_CID_25176
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C24H28N2O3
|
|||
Canonical SMILES |
COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC=CC4=CC=CC=C43)O
|
|||
InChI |
1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3
|
|||
InChIKey |
HRRBJVNMSRJFHQ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 57149-07-2
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:31891
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Metabolism of Drug Affected by Studied Microbe(s) | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Experimental Method | High-throughput screening | |||
Description | Naftopidil can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -4.006; p = 0.004). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
Studied Microbe: Akkermansia muciniphila ATCC BAA-835
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Experimental Method | High-throughput screening | |||
Description | Naftopidil can be metabolized by Akkermansia muciniphila ATCC BAA-835 (log2FC = -0.325; p = 0.022). | |||
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
Studied Microbe: Bifidobacterium longum
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bifidobacterium longum was decreased by Naftopidil dihydrochloride (adjusted p-values: 7.67E-06). |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adrenergic receptor alpha-1A (ADRA1A) | Target Info | Inhibitor | [4] |
KEGG Pathway | Calcium signaling pathway | |||
cGMP-PKG signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
AMPK signaling pathway | ||||
Adrenergic signaling in cardiomyocytes | ||||
Vascular smooth muscle contraction | ||||
Salivary secretion | ||||
Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
Reactome | Adrenoceptors | |||
G alpha (q) signalling events | ||||
G alpha (12/13) signalling events | ||||
WikiPathways | Monoamine GPCRs | |||
Calcium Regulation in the Cardiac Cell | ||||
GPCRs, Class A Rhodopsin-like | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Endothelin Pathways | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
AMPK Signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
REF 2 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
REF 4 | Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.